![]()
|
Report Date : |
22.03.2011 |
IDENTIFICATION DETAILS
|
Name : |
MINA PHARMACEUTICAL & CHEMICAL INDUSTRIES SAE |
|
|
|
|
Registered Office : |
El |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Year of Establishment : |
1986 |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacture of pharmaceuticals, chemicals and medical requisites. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 2,500,000 |
|
Status : |
Good |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2010
|
Country Name |
Previous Rating (30.09.2010) |
Current Rating (31.12.2010) |
|
|
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company Name : MINA PHARMACEUTICAL & CHEMICAL
INDUSTRIES SAE
Doing Business As :
MINA PHARM
Country of Origin :
Legal Form :
Egyptian Joint Stock Company
Registration Date :
1986
Commercial Registration Number : 55223
Authorised Capital :
£E 500,000,000
Issued Capital :
£E 102,913,000
Paid up Capital :
£E 102,913,000
Total Workforce :
650
Activities :
Manufacture of pharmaceuticals, chemicals and medical requisites.
Financial Condition :
Good
Payments :
Nothing detrimental uncovered
Operating Trend : Steady
Recommended Credit Limit :
US$ 2,500,000
MINA PHARMACEUTICAL & CHEMICAL INDUSTRIES SAE
DOING BUSINESS AS: MINA PHARM
Street :
Area :
Town :
Country :
Telephone : (20-2)
24143170/1/2/3/4/5
Facsimile : (20-2)
24143179
Email : mailbox@minapharm.com
Subject operates from a large suite of offices that are rented and located
in the Central Business Area of Cairo.
Branch Office (s)
Location Description
·
3rd
Industrial Zone A2
Sharkeya
Tenth of
Tel:
(20-15) 413115 / 412157 / 412158 / 413015
Fax:
(20-15) 413109
·
Tel:
(20-2) 25745903 / 25788050
Fax:
(20-2) 25788079
Name Position
· Dr Wafik Saad El
Bardissi Chairman
· Ibrahim El Bakri Director
· Dr Amr El
Shabrawishi Director
· Anwar Nasr
Mikhaiel Director
· Sameh George Finance
Manager
· Dr Philip Labib
Eskros Marketing
Manager
· Dr Wagih Hana Production
Manager
· Dr Ezzat Guirguis Maintenance
Manager
· Moustafa Habib IT
Manager
· Mariam Rimon Human
Resources Manager
Date of
Establishment : 1986
Legal Form : Egyptian Joint
Stock Company
Commercial Reg.
No. : 55223
Authorised Capital : £E 500,000,000
Issued Capital : £E 102,913,000
Paid up Capital : £E 102,913,000
· Members of the El
Bardissi family 50.0%
· Arab Moltaka
Investment 17.0%
· Members of the El
Shabrawishi family 12.5%
· Investia Bank 10.0%
· New Trend 4.5%
· Danish Domix 3.5%
· Local businessmen
and private investors 2.5%
Activities: Engaged in the manufacture and export of pharmaceuticals, chemicals and
medical requisites. Subject’s product range includes, cardiovascular products, coronary
vasodilators, anaesthetics, eye ointments and
drops, ophthalmic preparations, anti-diarrhoeal preparations, antacids
and preparations for gastric ulcers.
Import Countries: Europe,
International Agencies Held:
· Sanofi
· Boi
· Menarini
· Bracco
· Bausch & Lomb
· Schwarz Pharma
· Alcon
· Cilag
· OM
· Wyeth
· Yamanoushi
Export Countries:
Operating Trend: Steady
Subject has a workforce of approximately 650 employees.
Financial highlights provided by local sources are given below:
Currency: Egyptian Pounds (£E)
Year
Ending 31/12/09: Year
Ending 31/12/10:
Total Sales £E
342,842,000 £E
349,158,000
Local sources consider subject’s financial condition to be Good.
The above financial figures are based on estimations by our local
sources.
·
Bank of
Tel:
(20-2) 24824056 / 24836073
Fax:
(20-2) 24837468
·
Suez Canal Bank
PO Box: 2620
Tel: (20-2)
25769296
Fax: (20-2)
25322064
·
Commercial International Bank (CIB)
PO Box: 2430
Tel: (20-2) 25703043
Fax: (20-2) 25703172 / 25072691
No complaints regarding subject’s payments have been reported.
During the course of this investigation nothing detrimental was
uncovered regarding subject’s operating history or the manner in which payments
are fulfilled. As such the company is considered to be a fair trade risk.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.45.05 |
|
|
1 |
Rs.73.05 |
|
Euro |
1 |
Rs.63.81 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.